CA3063851C - Treatment of glaucoma - Google Patents

Treatment of glaucoma Download PDF

Info

Publication number
CA3063851C
CA3063851C CA3063851A CA3063851A CA3063851C CA 3063851 C CA3063851 C CA 3063851C CA 3063851 A CA3063851 A CA 3063851A CA 3063851 A CA3063851 A CA 3063851A CA 3063851 C CA3063851 C CA 3063851C
Authority
CA
Canada
Prior art keywords
dextran sulfate
pharmaceutically acceptable
acceptable salt
use according
glaucoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3063851A
Other languages
English (en)
French (fr)
Other versions
CA3063851A1 (en
Inventor
Lars Bruce
Adam Bruce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TX Medic AB
Original Assignee
TX Medic AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TX Medic AB filed Critical TX Medic AB
Priority claimed from PCT/SE2018/050506 external-priority patent/WO2018212708A1/en
Publication of CA3063851A1 publication Critical patent/CA3063851A1/en
Application granted granted Critical
Publication of CA3063851C publication Critical patent/CA3063851C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
CA3063851A 2017-05-17 2018-05-16 Treatment of glaucoma Active CA3063851C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1750615 2017-05-17
SE1750615-5 2017-05-17
US201762555848P 2017-09-08 2017-09-08
US62/555,848 2017-09-08
PCT/SE2018/050506 WO2018212708A1 (en) 2017-05-17 2018-05-16 Treatment of glaucoma

Publications (2)

Publication Number Publication Date
CA3063851A1 CA3063851A1 (en) 2018-11-22
CA3063851C true CA3063851C (en) 2023-09-19

Family

ID=62245395

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3063851A Active CA3063851C (en) 2017-05-17 2018-05-16 Treatment of glaucoma

Country Status (12)

Country Link
US (1) US11291684B2 (https=)
EP (1) EP3532072B1 (https=)
JP (1) JP6817466B2 (https=)
KR (1) KR102331421B1 (https=)
CN (1) CN110621320B (https=)
CA (1) CA3063851C (https=)
DK (1) DK3532072T3 (https=)
ES (1) ES2777836T3 (https=)
IL (1) IL270362B (https=)
PL (1) PL3532072T3 (https=)
PT (1) PT3532072T (https=)
RU (1) RU2759998C2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3074987A1 (en) * 2017-09-08 2019-03-14 Tx Medic Ab New use of dextran sulfate
GB202008919D0 (en) * 2020-06-11 2020-07-29 Univ Birmingham Polysaccharide conpositions and therapeutic gels
CN115531417B (zh) * 2022-11-14 2024-04-09 青岛海尔生物科技有限公司 ITGA6阳性iPSC源小梁网类细胞在制备治疗高眼压疾病药物中的应用及筛选方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4238482A (en) * 1978-09-29 1980-12-09 Peyman Gholam A Intraocular infusion irrigation solution and method
DE3705669A1 (de) 1987-02-21 1988-09-01 Thomae Gmbh Dr K Verwendung von dextransulfat zur herstellung eines arzneimittels zur behandlung und prophylaxe von gefaessverengungen und gefaessverschluessen
JPH02223525A (ja) * 1988-11-16 1990-09-05 Takeda Chem Ind Ltd 血管新生阻害剤
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
US5227372A (en) 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
CA2020199C (en) 1990-06-29 2002-08-20 Daniel Bar-Shalom Uses of sulphated sugars
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
CA2331620A1 (en) 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
GB9917092D0 (en) 1999-07-22 1999-09-22 Ml Lab Plc Treatment of angiogenesis-dependent conditions
WO2005110438A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
SE0401182D0 (sv) 2004-05-05 2004-05-05 Q Med Ab Novel use of a viscoelastic composition
US20060154894A1 (en) 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
WO2007002139A2 (en) 2005-06-22 2007-01-04 The Trustees Of The University Of Pennsylvania Neuroprotection of retinal ganglion cells
US20140186339A1 (en) * 2006-10-27 2014-07-03 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US20130273096A1 (en) 2011-10-05 2013-10-17 Bruce A. Daniels Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
EP3142684A4 (en) * 2014-05-12 2018-05-23 Purdue Research Foundation Selectin and icam/vcam peptide ligand conjugates
WO2015190989A1 (en) 2014-06-12 2015-12-17 Tx Medic Ab The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
SE538503C2 (en) 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate
SE539575C2 (en) * 2015-07-30 2017-10-17 Tx Medic Ab Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
CN107137421A (zh) 2017-05-25 2017-09-08 青岛市中心医院 硫酸葡聚糖在制备抑制角膜血管新生药物中的应用

Also Published As

Publication number Publication date
PL3532072T3 (pl) 2020-09-21
ES2777836T3 (es) 2020-08-06
EP3532072B1 (en) 2020-01-01
EP3532072A1 (en) 2019-09-04
KR102331421B1 (ko) 2021-11-25
IL270362B (en) 2021-04-29
BR112019024087A2 (pt) 2020-06-02
CN110621320A (zh) 2019-12-27
JP2020519742A (ja) 2020-07-02
RU2019136633A (ru) 2021-06-17
RU2759998C2 (ru) 2021-11-22
KR20200005560A (ko) 2020-01-15
US20210315920A1 (en) 2021-10-14
RU2019136633A3 (https=) 2021-06-17
PT3532072T (pt) 2020-03-05
US11291684B2 (en) 2022-04-05
CA3063851A1 (en) 2018-11-22
JP6817466B2 (ja) 2021-01-20
CN110621320B (zh) 2023-03-17
DK3532072T3 (da) 2020-04-06

Similar Documents

Publication Publication Date Title
Williams et al. Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma
Carido et al. Characterization of a mouse model with complete RPE loss and its use for RPE cell transplantation
Semeraro et al. Current trends about inner limiting membrane peeling in surgery for epiretinal membranes
Liu et al. Subretinal injection of amyloid-β peptide accelerates RPE cell senescence and retinal degeneration
CN112843085A (zh) 一种治疗视神经疾病的复合物及其制备方法和用途
CA3063851C (en) Treatment of glaucoma
Yan et al. Smart coating by thermo-sensitive Pluronic F-127 for enhanced corneal healing via delivery of biological macromolecule progranulin
Shang et al. PEDF gene deletion disrupts corneal innervation and ocular surface function
Yuan et al. Ic100, a humanized therapeutic monoclonal anti-asc antibody alleviates oxygen-induced retinopathy in mice
WO2018212708A1 (en) Treatment of glaucoma
Lin et al. NF-κB/IL-6 axis drives impaired corneal wound healing in aqueous-deficient dry eye
Namavari et al. Cyclosporine immunomodulation retards regeneration of surgically transected corneal nerves
Trofimova Molecular mechanisms of retina pathology and ways of its correction
Zhang et al. Involvement of endoplasmic reticulum stress in trigeminal ganglion corneal neuron injury in dry eye disease
Fan et al. [Retracted] Effects of Recombinant Human Epidermal Growth Factor Eye Drops Combined with Phacoemulsification on Short‐and Long‐Term Visual Acuity Recovery and Related Dry Eye Complications in Patients with Senile Cataract
Lin et al. Changes in PEDF, MMP-2, and TGF-β2 levels in the aqueous humor of cataract patients and their correlation with disease severity
BR112019024087B1 (pt) Uso de sulfato de dextrano ou de um sal farmaceuticamente aceitável do mesmo para tratamento, inibição ou prevenção de glaucoma
Xu et al. Association between anti‐fibrillin‐2 protein induced retinal degeneration via intravitreous delivery and activated TGF‐β signalling in mice
CN112569338B (zh) Tdfa在制备预防和/或治疗眼表炎症疾病的药物中的应用
EP4659755A1 (en) Therapeutic drug for retinal pigment epithelium tears
Echevarria The Role of Interleukin-6 in Health and Disease of Retinal Ganglion Cells
Xiao-Chen et al. A New Experimental Model of Krypton Laser-Induced Choroidal Neovascularization in Tree Shrew
LIU et al. A New Experimental Model of Krypton Laser-Induced Choroidal Neovascularization in Tree Shrew
Nischal Recent advances in pediatric ophthalmology
Adlju et al. Comparing the mid-term efficacy and safety of the Stegmann Canal Expander Canaloplasty with the prolene suture Canaloplasty in cases of open angle glaucoma

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220815

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250429

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250429